Results 191 to 200 of about 8,056,631 (393)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Nanotechnology for Nasopharyngeal Cancer Therapy and Improving Drug Stability and Biodistribution [PDF]

open access: bronze
Minmin Shao   +11 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Stability-indicating HPLC-DAD method for the simultaneous determination of fluoroquinolone in combination with a non-steroidal anti-inflammatory drug in pharmaceutical formulation [PDF]

open access: diamond, 2020
Elaine de Oliveira Araujo   +6 more
openalex   +2 more sources

Multi-access drug delivery network and stability

open access: yesInternational Journal of Nanomedicine, 2011
S Mitatha1, N Moongfangklang1, MA Jalil2, N Suwanpayak3, J Ali4, PP Yupapin31Hybrid Computing Research Laboratory, Faculty of Engineering, King Mongkut’s Institute of Technology Ladkrabang, Bangkok, Thailand; 2Ibnu Sina Institute of Fundamental
Ali J   +5 more
doaj  

Evaluation of Dosage and Stability of Drugs Prepared by Modification of Commercial Drugs for Administration to Patients in Pediatrics Clinic

open access: diamond, 2023
Fatma KURUDIREK   +4 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

open access: yesMolecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Interplay between RNA‐protein interactions and RNA structures in gene regulation

open access: yesFEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy